BeiGene
BGNE
#934
Rank
โ‚ฌ19.95 B
Marketcap
179,33ย โ‚ฌ
Share price
-2.10%
Change (1 day)
-3.22%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : โ‚ฌ3.19 Billion

According to BeiGene 's latest financial reports the company has โ‚ฌ3.19 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚ฌ3.19 B-21.69%
2022-12-31$โ‚ฌ4.08 B-24.54%
2021-12-31$โ‚ฌ5.41 B72.14%
2020-12-31$โ‚ฌ3.14 B260.19%
2019-12-31$โ‚ฌ0.87 B-43.03%
2018-12-31$โ‚ฌ1.53 B168.81%
2017-12-31$โ‚ฌ0.57 B69.97%
2016-12-31$โ‚ฌ0.33 B393.61%
2015-12-31$โ‚ฌ67.97 M220.81%
2014-12-31$โ‚ฌ21.18 M-175.56%
2013-12-31$-โ‚ฌ28.05 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚ฌ5.7 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.32 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA